α1-Blocker therapy in the nineties: Focus on the disease

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue , 1999, Pages S9-S15

  Höfner, Klaus ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

5 reductase inhibitors; Acute urinary retention; Benign prostatic hyperplasia; LUTS; Prostate; 1 blockers

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ASTHENIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; IMPOTENCE; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SOMNOLENCE; TRANSURETHRAL RESECTION; URINE RETENTION; VERTIGO;

EID: 1642633642     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500368     Document Type: Article

References (33)

1. Holtgrewe HL et al. The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In: Denis L et al (eds). 4th International Consultation of Benign Prostatic Hyperplasia. Paris, July 2-5, 1997. Health Publications Ltd, 1998, pp 63-81.
2. Health Care Financing Administrations. B.E.S.S. Data: Washington, DC, 1995.
3. Kaplan SA, Goluboff ET. Effects of demographic factors, urinary peak low rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia. Urology 1995; 45: 398-405.
4. Denis L et al. 4th International Consultation on Benign Prostatic Hyperplasia. Paris, July 2-5, 1997. Health Publications Ltd, 1998, p 667.
5. McConnell JD et al. Benign prostatic hyperplasia: diagnosis and treatment. AHCPR publication no 94-053. No8 Rockville. Department of Health and Human Services, 1994.
6. Teillac P, Delauche-Cavallier MC, Attali P. Urinary low rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. Br J Urol 1992; 70: 58-64.
7. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC and the ALGEBI Study Group. Efficacy and safety of sustained-release alfuzosin 5mg in patients with benign prostatic hyperplasia. Eur Urol 1997; 31: 190-198.
8. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 1998; 51: 901-906.
9. Lepor H et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med 1996; 335: 533-539.
10. Fawzy A et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105-109.
11. Chapple CR, Andersson KE. a-Blocker clinical results. In: Denis L et al (eds). 4th International Consultation of Benign Prostatic Hyperplasia. Paris, July 2-5, 1997. Health Publications Ltd, 1998, pp 610-632.
12. Martorana G et al. Effects of short-term treatment with alpha-1 blocker alfuzosin on urodynamic pressure/low parameters in patients with benign prostatic hyperplasia. Eur Urol 1997; 32: 47-53.
13. 1-Adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 587-596.
14. Witjes WPJ et al. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology 1997; 49: 197-206.
15. Gerber GS et al. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin. Urology 1996; 47: 840-844.
16. Debruyne FMJ et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998; 34: 169-175.
17. Kirby RS et al. Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. J Urol 1999; 161 (Suppl): 266.
18. Boyle P, Gould A, Roehrborn C. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
19. Padley RJ et al. A meta-analysis of the effect of terazosin versus placebo on symptoms and low rate in randomized, placebocontrolled trials. J Urol 1998; 159 (Suppl 5): 257.
20. 1 adrenergic receptors in human benign prostatic hyperplasia. J Urol 1984; 132: 1226-1229.
21. Lipstitz LA. Orthostatic hypotension in the elderly. N Engl J Med 1989; 321: 952-956.
22. Buzelin JM et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997; 80: 597-605.
23. Chapple CR et al. Tamsulosin 0.4mg once daily: Tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol 1997; 32: 462-470.
24. Jardin A. Alfuzosin. In: Kirby RS et al (eds). Textbook of Benign Prostatic Hyperplasia, 2nd Edition, 1999 (in press). ISIS Medical Media: Oxford.
25. Jacobsen SJ et al. Natural history of prostatism: risk factors of acute urinary retention. J Urol 1997; 158: 481-487.
26. Roehrborn CG et al. Serum prostatic-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53: 473-480.
27. Kolman C, Girman CJ, Jacobsen SJ, Lieber MM. Distribution of post-void residual urine volume in randomly selected men. Urology 1999; 161: 122-127.
28. McConnell JD et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men withbenign prostatichyperplasia.NEngl JMed1998; 338: 557-563.
29. Caine M. Alpha-adrenergic mechanisms in dynamics of benign prostatic hyperplasia. Urology 1988; 32: 16-20.
30. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P and the BPH-ALF Group. Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 1991; 337: 1457-1461.
31. Lukacs B, Grange JC, Comet D, McCarthy C and the BPH Group in General Practice. Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in general practice. PCPD 1998; 5: 276-283.
32. Wasson JH et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med 1995; 332: 75-79.
33. Mc Neil SA et al. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebocontrolled trial. BJU International 1999; 84: 622-627.